Education
About Us
Working with TipRanks
Follow Us
Amneal Pharmaceuticals Inc (AMRX)
NASDAQ:AMRX
Earnings Data
Report Date
May 02, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.16Last Year’s EPS
0.14Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 28, 2025
|% Change Since: 3.34%
|Next Earnings Date:May 02, 2025
Earnings Call Sentiment|Positive
Amneal Pharmaceuticals had a strong year with significant growth and successful new product launches, particularly Crexent. They made strategic entries into new markets and achieved financial improvements. However, challenges such as the upcoming Rytary loss of exclusivity and slow progress in the Naloxone market were noted.Company Guidance
During the Amneal Pharmaceuticals, Inc. fourth quarter 2024 earnings call, the company provided guidance for 2025, highlighting expectations for continued growth across its business segments. The company anticipates total net revenue for 2025 to reach between $3.0 to $3.1 billion, representing a growth of 7% to 11%. The affordable medicine segment is projected to maintain double-digit growth, driven by recent and upcoming product launches, as well as biosimilar and injectable expansions. The specialty segment is expected to generate approximately $400 million, with Crexent sales anticipated at around $50 million. Additionally, the RevCare segment is forecasted to continue its double-digit growth trajectory. Amneal also expects adjusted EBITDA between $650 and $675 million, a 4% to 8% increase, and plans to maintain adjusted gross margins between 41% to 42%. The company aims to reduce its net leverage to below four times, further enhancing its financial position.Stellar Financial Performance in 2024
Amneal Pharmaceuticals delivered double-digit revenue and adjusted EBITDA growth in 2024, with net leverage reduced below four times.
Successful Launch of Crexent
Crexent was launched successfully, achieving about 1% market share in four months and projected to reach over 3% by year-end. Expected US peak sales are between $300 to $500 million.
Entry into High-Growth Weight Loss Market
Amneal entered the weight loss and obesity space through a strategic collaboration with Medcera, aiming to leverage the projected $150 billion global market by 2030.
Double-Digit Growth in All Segments
The affordable medicine segment grew by 15%, specialty by 14%, and RevCare by 25% in 2024.
Strong Q4 Revenue Growth
Q4 revenues grew by 18%, driven by new product launches and biosimilars, with biosimilars revenue increasing by 49%.
Deleveraging Success and Credit Rating Upgrade
Amneal reduced net leverage from 4.8 times to 3.9 times and received credit rating upgrades from S&P and Moody's.
---
AMRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 28, 2025 | $8.38 | $8.67 | +3.46% |
| Nov 08, 2024 | $8.61 | $8.73 | +1.39% |
| Aug 09, 2024 | $7.77 | $7.65 | -1.54% |
| May 03, 2024 | $6.21 | $6.76 | +8.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amneal Pharmaceuticals Inc (AMRX) report earnings?
Amneal Pharmaceuticals Inc (AMRX) is schdueled to report earning on May 02, 2025, TBA Not Confirmed.
What is Amneal Pharmaceuticals Inc (AMRX) earnings time?
Amneal Pharmaceuticals Inc (AMRX) earnings time is at May 02, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMRX EPS forecast?
AMRX EPS forecast for the fiscal quarter 2025 (Q1) is 0.16.
---
